Cue Biopharma, Inc. Research and Development Expense
Cue Biopharma, Inc. (CUE) reported Research and Development Expense of $49.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Cue Biopharma, Inc. research and development expense for the quarter ending 2026-06-30 was $49.01M, a 519.56% increase year-over-year.
- Cue Biopharma, Inc. research and development expense for the quarter ending 2026-03-31 was $6.90M, a 19.31% decline year-over-year.
- Cue Biopharma, Inc. research and development expense for the quarter ending 2025-12-31 was $16.53M, a 130.12% increase year-over-year.
- Cue Biopharma, Inc. research and development expense for the quarter ending 2025-09-30 was $4.75M, a 49.32% decline year-over-year.
- Cue Biopharma, Inc. research and development expense for fiscal 2025 was $37.74M, a 3.99% increase from fiscal 2024.
- Cue Biopharma, Inc. research and development expense for fiscal 2024 was $36.30M, a 11.05% decline from fiscal 2023.
- Cue Biopharma, Inc. research and development expense for fiscal 2023 was $40.80M, a 5.76% increase from fiscal 2022.
- Cue Biopharma, Inc. research and development expense for fiscal 2022 was $38.58M, a 6.70% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $49.01M 10-Q · filed 2026-08-14 | $55.90M 10-Q · filed 2026-08-14 | $72.44M derived: sum of 3 quarters · filed 2026-08-14 | $77.19M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $6.90M 10-Q · filed 2026-05-14 | $23.43M derived: sum of 2 quarters · filed 2026-05-14 | $28.18M derived: sum of 3 quarters · filed 2026-05-14 | $36.09M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $16.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $21.29M derived: sum of 2 quarters · filed 2026-03-16 | $29.20M derived: sum of 3 quarters · filed 2026-08-14 | $37.74M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $4.75M 10-Q · filed 2025-11-12 | $12.66M derived: sum of 2 quarters · filed 2026-08-14 | $21.21M 10-Q · filed 2025-11-12 | $28.39M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $7.91M 10-Q · filed 2026-08-14 | $16.46M 10-Q · filed 2026-08-14 | $23.64M derived: sum of 3 quarters · filed 2026-08-14 | $33.02M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $8.55M 10-Q · filed 2026-05-14 | $15.73M derived: sum of 2 quarters · filed 2026-05-14 | $25.11M derived: sum of 3 quarters · filed 2026-05-14 | $34.64M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $16.57M derived: sum of 2 quarters · filed 2026-03-16 | $26.09M derived: sum of 3 quarters · filed 2026-03-16 | $36.30M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $9.38M 10-Q · filed 2025-11-12 | $18.91M derived: sum of 2 quarters · filed 2025-11-12 | $29.11M 10-Q · filed 2025-11-12 | $40.00M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $9.53M 10-Q · filed 2025-08-12 | $19.73M 10-Q · filed 2025-08-12 | $30.62M derived: sum of 3 quarters · filed 2025-08-12 | $40.49M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $10.20M 10-Q · filed 2025-05-12 | $21.09M derived: sum of 2 quarters · filed 2025-05-12 | $30.96M derived: sum of 3 quarters · filed 2025-05-12 | $41.61M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $20.76M derived: sum of 2 quarters · filed 2025-03-31 | $31.41M derived: sum of 3 quarters · filed 2025-03-31 | $40.80M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $9.87M 10-Q · filed 2024-11-14 | $20.52M derived: sum of 2 quarters · filed 2024-11-14 | $29.91M 10-Q · filed 2024-11-14 | $41.25M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $10.65M 10-Q · filed 2024-08-14 | $20.04M 10-Q · filed 2024-08-14 | $31.37M derived: sum of 3 quarters · filed 2024-08-14 | $38.94M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $9.39M 10-Q · filed 2024-05-09 | $20.72M derived: sum of 2 quarters · filed 2024-05-09 | $28.29M derived: sum of 3 quarters · filed 2024-05-09 | $37.89M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $11.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $18.90M derived: sum of 2 quarters · filed 2024-03-28 | $28.50M derived: sum of 3 quarters · filed 2024-03-28 | $38.58M 10-K · filed 2024-03-28 | $38.58M 10-K · filed 2023-03-21 |
| 2022-09-30 | $7.57M 10-Q · filed 2023-11-03 | $17.16M derived: sum of 2 quarters · filed 2023-11-03 | $27.25M 10-Q · filed 2023-11-03 | $38.75M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $9.59M 10-Q · filed 2023-08-08 | $19.68M 10-Q · filed 2023-08-08 | $31.17M derived: sum of 3 quarters · filed 2023-08-08 | $42.46M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $10.08M 10-Q · filed 2023-05-09 | $21.58M derived: sum of 2 quarters · filed 2023-05-09 | $32.87M derived: sum of 3 quarters · filed 2023-05-09 | $41.63M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $22.79M derived: sum of 2 quarters · filed 2023-03-21 | $31.55M derived: sum of 3 quarters · filed 2023-03-21 | $41.35M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $11.29M 10-Q · filed 2022-11-14 | $20.05M derived: sum of 2 quarters · filed 2022-11-14 | $29.85M 10-Q · filed 2022-11-14 | $37.87M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $8.76M 10-Q · filed 2022-08-04 | $18.58M 10-Q · filed 2022-08-04 | $26.58M derived: sum of 3 quarters · filed 2022-08-04 | $34.10M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $9.82M 10-Q · filed 2022-05-10 | $17.82M derived: sum of 2 quarters · filed 2022-05-10 | $25.34M derived: sum of 3 quarters · filed 2022-05-10 | $33.46M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $15.52M derived: sum of 2 quarters · filed 2022-03-16 | $23.64M derived: sum of 3 quarters · filed 2022-03-16 | $33.55M 10-K · filed 2022-03-16 | |
| 2020-09-30 | $7.52M 10-Q · filed 2021-11-09 | $15.64M derived: sum of 2 quarters · filed 2021-11-09 | $25.54M 10-Q · filed 2021-11-09 | $32.51M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $8.12M 10-Q · filed 2021-08-09 | $18.02M 10-Q · filed 2021-08-09 | $24.99M derived: sum of 3 quarters · filed 2021-08-09 | $30.29M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $9.91M 10-Q · filed 2021-05-10 | $16.87M derived: sum of 2 quarters · filed 2021-05-10 | $22.17M derived: sum of 3 quarters · filed 2021-05-10 | $29.04M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $12.27M derived: sum of 2 quarters · filed 2021-03-09 | $19.13M derived: sum of 3 quarters · filed 2021-03-09 | $27.49M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $5.30M 10-Q · filed 2020-11-09 | $12.17M derived: sum of 2 quarters · filed 2020-11-09 | $20.52M 10-Q · filed 2020-11-09 | $27.35M derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $6.87M 10-Q · filed 2020-08-07 | $15.22M 10-Q · filed 2020-08-07 | $22.04M derived: sum of 3 quarters · filed 2020-08-07 | $32.36M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | $8.35M 10-Q · filed 2020-05-07 | $15.18M derived: sum of 2 quarters · filed 2020-05-07 | $25.49M derived: sum of 3 quarters · filed 2020-05-07 | $30.90M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $17.14M derived: sum of 2 quarters · filed 2020-03-12 | $22.55M derived: sum of 3 quarters · filed 2020-03-12 | $28.54M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $10.31M 10-Q · filed 2019-11-07 | $15.73M derived: sum of 2 quarters · filed 2019-11-07 | $21.72M 10-Q · filed 2019-11-07 | $30.57M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $5.41M 10-Q · filed 2019-08-08 | $11.41M 10-Q · filed 2019-08-08 | $20.25M derived: sum of 3 quarters · filed 2019-08-08 | $24.25M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $5.82M 10-Q · filed 2019-05-08 | $14.84M derived: sum of 2 quarters · filed 2019-05-08 | $18.84M derived: sum of 3 quarters · filed 2019-05-08 | $22.26M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $9.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $13.02M derived: sum of 2 quarters · filed 2019-03-14 | $16.44M derived: sum of 3 quarters · filed 2019-03-14 | $18.90M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $4.00M 10-Q · filed 2018-11-13 | $7.42M derived: sum of 2 quarters · filed 2018-11-13 | $9.88M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $3.42M 10-Q · filed 2018-08-13 | $5.88M 10-Q · filed 2018-08-13 | |||
| 2017-03-31 | $2.46M 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |